Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 136 clinical trials
None
Pre Operative Trastuzumab in Operable Breast Cancer

monoclonal antibody against the human epidermal growth factor receptor 2 (HER2/erbB-2),which has shown in both in vitro assays and in animals, to inhibit the proliferation of human tumour cells that

cancer
platelet count
epidermal growth factor
gene amplification
trastuzumab
  • 71 views
  • 26 Jan, 2021
  • 1 location
None
Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer

This is a prospective, multisite, randomized, open-label Phase III clinical trial (CLOVER study) comparing 4 cycles with 6 cycles of TC (docetaxel+cyclophosphamide) adjuvant chemotherapy for 1-3 positive lymph node, ER+/HER2- early breast cancer patients.

progesterone receptor
erbb2
ki-67
chromogenic in situ hybridization
cancer surgery
  • 5 views
  • 24 Jan, 2021
  • 14 locations
None
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans, and will be in two parts. The primary purpose of the parts are: Dose Escalation: To …

progesterone receptor
lung carcinoma
cancer
estrogen receptor
erbb2
  • 260 views
  • 01 Dec, 2021
  • 8 locations
None
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.

lung carcinoma
erbb2
measurable disease
epidermal growth factor
pembrolizumab
  • 0 views
  • 19 Nov, 2021
  • 21 locations
None
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

Capecitabine combined with pyrotinib is the standard protocol for HR+/HER2+ advanced breast cancer after trastuzumab failure, but the incidence of grade 3 hand-foot-syndrome was 16.4%. Therefore, the search for efficient and low toxicity alternatives has become a research hotspot. Our previous basic studies have shown that ER inhibitor fulvestrant and …

  • 0 views
  • 26 Jan, 2021
  • 1 location
None
De-Escalation of Breast Radiation Trial for Hormone Sensitive HER-2 Negative Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

  • 0 views
  • 23 Nov, 2021
  • 1 location
None
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)

This is a phase II open-label, multicentre, randomized trial. The study assesses the treatment of postmenopausal patients with hormone receptor positive/HER2 positive early breast cancer with neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade, versus the treatment with paclitaxel in combination with HER2 blockade.

palbociclib
pertuzumab
cancer
estrogen receptor
erbb2
  • 17 views
  • 26 Oct, 2021
  • 63 locations
None
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating …

axillary lymph node dissection
progesterone receptor
cancer
mastectomy
estrogen receptor
  • 784 views
  • 10 Oct, 2021
  • 127 locations
None
Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy

The aim of this study is to assess whether, omitting further axillary treatment (ALND and ART) for patients with early stage breast cancer and axillary nodal metastases on needle biopsy, who after NACT have no residual cancer in the lymph nodes on sentinel node biopsy, is non-inferior to axillary treatment …

axillary lymph node dissection
progesterone receptor
cancer
breast cancer staging
estrogen receptor
  • 0 views
  • 25 Oct, 2021
  • 3 locations
None
Nivolumab Ipilimumab and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

The goal of this protocol is to evaluate the safety and efficacy of an alternative systemic combination approach that omits or delays the use of chemotherapy in metastatic disease, while improving efficacy and durability of response. The approach combines two potentially effective and previously studied strategies: androgen receptor blockade and …

bicalutamide
cancer
mammogram
growth factor
erbb2
  • 0 views
  • 25 Jan, 2021
  • 1 location